Simpson Thacher & Bartlett LLP

Litigation/Antitrust and Trade Regulation

Abram Ellis is a Litigation Partner in the Firm’s Washington, D.C. office who is recognized as a “Rising Star” and “Next Generation Partner” in antitrust litigation and cartels. His antitrust practice comprises all aspects of competition law, from defending clients against complex class action antitrust litigation to helping clients obtain regulatory clearance from domestic and international competition authorities for significant transactions. Abram is particularly experienced in antitrust litigation involving complex financial instruments, the healthcare industry and employment issues.

In addition to his robust antitrust practice, Abram advises clients on a range of litigation and regulatory matters. As Co-Head of the Firm’s International Trade Regulation Practice, he advises leading private equity funds, financial institutions and major corporations on regulatory and compliance matters relating to cross-border activities, including with respect to tariffs, anti-money laundering, OFAC, FCPA, the Outbound Investment Rule, the DOJ’s Data Security Program and export matters.

Recent representations include: RPM International and the Euclid Chemical Company in winning the dismissal of an antitrust class action; JPMorgan in summary judgement in a LIBOR lawsuit; and separately, JPMorgan in obtaining the Ninth Circuit’s affirmance of dismissal in an ICE LIBOR lawsuit against several major banks, which was named “Litigation of the Year – Cartel Defense” at GCR Awards 2025; and Change Healthcare in its $13.8 billion acquisition by UnitedHealth Group, which was named “Merger Control Matter of the Year – Americas” at Global Competition Review’s GCR Awards 2023.

Joined the Firm in 2009.

New York State Bar Association

University of Michigan Law School (J.D., cum laude, 2005); Johns Hopkins School of Advanced International Studies (M.A., 2002), John C. Foster Award, SAIS Review Book Review Editor; Brigham Young University (B.A., 2000).